Trivant Custom Portfolio Group LLC Acquires 5,693 Shares of Sanofi (NASDAQ:SNY)

Trivant Custom Portfolio Group LLC raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 47.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,680 shares of the company's stock after purchasing an additional 5,693 shares during the quarter. Trivant Custom Portfolio Group LLC's holdings in Sanofi were worth $981,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lee Danner & Bass Inc. purchased a new position in shares of Sanofi during the 4th quarter worth approximately $31,000. Bessemer Group Inc. increased its position in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after acquiring an additional 242 shares during the last quarter. UMB Bank n.a. increased its position in shares of Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after acquiring an additional 264 shares during the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $76,000. Finally, Kestra Investment Management LLC purchased a new stake in shares of Sanofi during the fourth quarter worth about $84,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Up 0.5%

SNY traded up $0.24 during trading on Friday, hitting $47.86. The company had a trading volume of 5,607,107 shares, compared to its average volume of 2,379,230. The company has a market capitalization of $117.37 billion, a PE ratio of 17.09, a PEG ratio of 0.98 and a beta of 0.50. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm's 50-day moving average price is $51.23 and its 200 day moving average price is $52.03. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period last year, the business posted $1.78 earnings per share. The business's revenue for the quarter was down 11.0% compared to the same quarter last year. As a group, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a $2.0369 dividend. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. Sanofi's dividend payout ratio is 57.14%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on SNY shares. The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective for the company. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Finally, Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Three analysts have rated the stock with a hold rating, three have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.